Ratos owns 97.57% of the capital and votes in Biolin Scientific after the extended acceptance period
(Thomson Reuters ONE) -
This information is disclosed in accordance with the Securites Markets Act and
NASDAQ OMX Stockholm's rules regarding public offers on the stock market.
This press release may not be distributed, directly or indirectly, in or into,
Australia, Canada, Japan, New Zealand, South Africa, Switzerland or the United
States of America. The Offer is not being made to (and acceptances will not be
accepted from) persons in those countries or in any other country where the
making of the Offer, the distribution of this press release or acceptance of the
Offer requires further offer documents, filings or other measures in addition to
those required by Swedish law.
Ratos owns a total of 25 936 144 shares and convertibles, corresponding to
97.57% of all shares and votes in Biolin Scientific following the end of the
extended acceptance period. Settlement in respect of those that accepted the
offer during the extended acceptance period is expected to commence on 3 March
2011.
Based on the final review of acceptances received during the extended acceptance
period, which ended on 24 February 2011, an additional 555 623 shares and
convertibles, corresponding to 2.09% of all shares and votes in Biolin
Scientific, have been tendered in the offer. This means that the offer has been
accepted by owners of a total of 25 198 458 shares and convertibles,
corresponding to 94.80% of the capital and votes in Biolin Scientific. Together
withshares acquired outside the offer on NASDAQ OMX at a price of SEK 11.50 per
share, Ratos now owns 97.57% of all capital and votes (after full dilution).
For those who have accepted the offer during the extended acceptance period,
settlement is expected to commence on 3 March 2011.
The acceptance period will not be extended further. Ratos has initiated
compulsory acquisition of the remaining shares.
For further information, please contact:
Arne Karlsson, CEO, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20
Financial calendar from Ratos:
Annual General Meeting 2011 5 April 2011
Interim Report January - March 2011 5 May 2011
Interim Report January - June 2011 19 August 2011
Interim Report January - September 2011 9 November 2011
Ratos is a private equity conglomerate. The company's mission is to maximise
shareholder value over time through the professional, active and responsible
exercise of its ownership role in primarily medium to large unlisted Nordic
companies. Ratos's holdings include AH Industries, Anticimex, Arcus-Gruppen,
Biolin Scientific, Bisnode, Contex, DIAB, EuroMaint, GS-Hydro, Hafa Bathroom
Group, HL Display, Inwido, Jøtul, KVD Kvarndammen, Lindab, Medisize, Mobile
Climate Control, SB Seating, Stofa and Other holdings. Ratos is listed on NASDAQ
OMX Stockholm and market capitalisation amounts to approximately SEK 37 billion.
Press release PDF:
http://hugin.info/1180/R/1492615/428400.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ratos via Thomson Reuters ONE
[HUG#1492615]
Unternehmensinformation / Kurzprofil:
Datum: 28.02.2011 - 08:30 Uhr
Sprache: Deutsch
News-ID 51950
Anzahl Zeichen: 3869
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ratos owns 97.57% of the capital and votes in Biolin Scientific after the extended acceptance period"
steht unter der journalistisch-redaktionellen Verantwortung von
Ratos (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
